BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for BNTX. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: BNTX is a Buy candidate.
BNTX stock price ended at $92.18 on 星期三, after rising 0.91%
On the latest trading day Aug 05, 2026, the stock price of BNTX rose by 0.91%, climbing from $91.42 to $92.18. Throughout the session, the stock experienced a volatility of 2.83%, with prices fluctuating between a daily low of $90.40 and a high of $92.96. Alongside this price increase, trading volume also rose by 299.3K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 1.7M shares were traded, amounting to a market value of approximately $23.3B.